Jonathan Y. Zhao, PhD
Dr. Yining (Jonathan) Zhao (趙奕寧), Ph.D., Co-founder and CEO of Heranova Lifesciences Ltd., an innovative Women’s Health company based in Boston and Hong Kong. He serves as the Co-founder, Chairman of the Board of Transcenta Holding Ltd (创胜集团，6628.HK), a biologic innovative company focused on cancer and bone diseases. He has been an independent board member of Alebund Pharmaceutics Inc since 2021. He has been a member of the Executive Board of the MIT Sloan School of Management since 2017, and a member of BayHelix Group since 2011.
Dr. Zhao was the Co-founder and Managing Director of Hangzhou Veritas-Igenomix Inc (杭州奕真生物科技有限公司) from May 2015 to Nov 2021 when it was acquired by Vitrolife AB (VITR.STO). And he was the Co-founder of Just Biotherapeutics based in Seattle from May 2015 to Jan 2019 when it was acquired by Evotech SE (EVO.NASDAQ). Dr. Zhao was the venture partner of Lilly Asia Ventures from May 2015 to May 2018 to build US-China cross-border biotech companies.
Prior to his entrepreneurial career, Dr. Zhao served as an Executive Director of Global Commercial Operations at Amgen Inc. from 2012 to 2015. He worked successively as an Associate Research Fellow and Team Leader, Director of biosimilar strategy and the Leader of Asia strategy at Pfizer from 2004 to 2012. Dr. Zhao served as the Research Scientist III at the R&D at Amgen Inc. from 1999 to 2004. He worked as the Assistant Manager of supply chain group at Shanghai Johnson & Johnson from 1994 to 1995.
Dr. Zhao received his Bachelor of Science in medicinal chemistry from Shanghai Medical University (上海醫科大學), in July 1994 and Ph.D. in analytical chemistry from Ghent University (Belgium) in November 1999. He received an MBA from the MIT Sloan School of Management in June 2008.